A new study tested the immune response of people who received a second vaccination with BioNTech-Pfizer after the first Oxford-AstraZeneca shot. The results are promising.
Vaccination is our best hope to stop the COVID-19 health crisis, and the rapid development of vaccines, supported by decades of coronavirus research, has made this possible. .. Scientists are also tracking various side effects as different vaccines are being deployed to control the pandemic. One of the rare but deadly blood coagulation reactions called vaccine-induced immune thrombotic thrombocytopenia is said to be caused by the Oxford-AstraZeneca and Johnson & Johnson COVID-19 vaccines. Young women face the highest risk.
But why do these Blood clot Occur? Some scientists believe that adenovirus-based vaccines such as Oxford-AstraZeneca and Johnson & Johnson have problems with the antibodies they produce against a cell signaling protein called platelet factor 4. These antibodies can be amplified when someone receives a booster shot. RNA-based vaccines do not cause this problem, so people whose first shot was an adenovirus-based vaccine are advised to take an mRNA vaccine booster shot instead. The German Vaccination Standing Committee is responsible for issuing national recommendations on the use of licensed vaccines, with people under the age of 60 first vaccinated in Oxford-AstraZeneca receiving the mRNA vaccine 12 weeks later. I advised that I should receive it.
In light of these developments, a German study supported by the EU-funded VACCELERATE project tested the immune response of people receiving mixed-and-match vaccines. As part of the study, researchers took blood samples from 500 people who received a second vaccination with the BioNTech-Pfizer mRNA vaccine nine weeks after the first Oxford-AstraZeneca shot.
Mix and match option results in a high immune response
The result was quite encouraging. Levels of neutralizing antibodies (antibodies that protect cells from bacteria and viruses) were much higher than those who received two doses of either vaccine. “This vaccination scheme is an interesting option when there is concern about the risk of thrombosis caused by adenoviral vector-based vaccines. vaccination “Insufficiency,” the authors report in a study. “But further research needs to address the safety and clinical efficacy of heterologous vaccination regimens.” The study was published in the journal. Lancet infection..
“The results of this study have a direct impact on our vaccination strategy,” said Bernd Sibler, Minister of Science and Arts of Bavaria, on the web of one of the major universities, Friedrich-Alexander-Universität Erlangen-Nürnberg. It is stated in the news article posted on the site. the study. “They help us use vaccination as effectively as possible, Political decision About future vaccination strategies. The work of medical and university hospital scientists is essential to finding a way out of the COVID-19 pandemic. ”
Heterogeneous prime boost vaccination with Matthias Tenbusch et al, ChAdOx1 nCoV-19 and BNT162b2, Lancet infection (2021). DOI: 10.1016 / S1473-3099 (21) 00240-5
Quote: How effective is the mixed and match vaccine against COVID-19? (September 2, 2021) Obtained September 2, 2021 from https: //medicalxpress.com/news/2021-09-effective-mix-and-match-vaccines-covid-.html
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.
How effective are mix-and-match vaccines against COVID-19? Source link How effective are mix-and-match vaccines against COVID-19?